Not Yet RecruitingNot Applicable

Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis

52 participantsStarted 2025-06-01

Plain-language summary

This study aims to evaluate, through a multicenter, prospective, double-blind, randomized, placebo-controlled clinical trial, whether immunosuppressive therapy improves target lesion-related cardiovascular outcomes compared to placebo treatment in patients with Rapid rEcurrence of Coronary Unexplained in-stent Restenosis (RECUR).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years old
✓. Able to understand the trial design and sign an informed consent form
✓. Patients meeting the RECUR definition
✓. Satisfactory results from revascularization within the past two weeks
✓. Receiving standard secondary prevention medication for coronary heart disease with treatment targets achieved

What they're measuring

Target vessel failure (TVF)

Timeframe: During the 1 year follow-up

Trial details

NCT IDNCT06981845

SponsorChina National Center for Cardiovascular Diseases

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2028-06-01

View on ClinicalTrials.gov More In-stent Restenosis Lesion trials